Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics peanut allergy vaccine to move into phase I trials after pre-clinical success

The company is developing Polyvac as a short course of injections that is safer and more effective than the current treatments.
Allergy Therapeutics peanut allergy vaccine to move into phase I trials after pre-clinical success
The salted killer - hundreds die annually from food allergies

Allergy Therapeutics (LON:AGY) will take its Polyvac vaccine for peanut allergy into a phase I clinical trial after it delivered positive pre-clinical results.

The findings showed a single dose of the company's unique adjuvant when combined with recombinant peanut allergen successfully protected against the serious allergic reaction anaphylaxis.

The company is developing Polyvac as a short course of injections that is safer and more effective than the current treatments.

“Hundreds of patients die each year in the United States as a result of food allergies (mainly peanut) and we are committed to saving these lives,” said Allergy Therapeutics chief executive Manuel Llobet.

“This peanut vaccine programme complements our current range of marketed ultra-short course vaccines in terms of safety, efficacy and improved patient convenience."

The shares rose 6% in afternoon trade to 27.5p. However the company’s broker, finnCap, thinks they have further to go.

Analyst Mark Brewer points out Allergy trades on an enterprise value/sales multiple of just two-times when its peers are on 3.2-times.

He reckons the shares are worth 43p each with “substantial further upside” as its hay fever drug Pollinex Quattro progresses through the development phases.

“We currently attribute no value to Polyvac Peanut and will re-assess as it moves into human studies,” said Brewer.

---addds broker comment, share price---

Ian_55ae0ddd437b7.jpg
Why Invest In Allergy Therapeutics plc? Read More Here

Register here to be notified of future AGY Company articles
View full AGY profile View Profile

Allergy Therapeutics plc Timeline

Related Articles

picture of an affimer
April 03 2017
Avacta has developed an innovative protein-scaffold platform, with potential applications in the life sciences research, diagnostic and therapeutic markets
Pollen2.jpg
January 19 2017
Turnover was £40.4mln in the six months to December
picture of pregnant women
May 09 2017
Diclectin is entering a potential £250mln UK/European market with a differentiated product addressing an unmet need.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use